W. Griffith Humphreys
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
W. Griffith Humphreys has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Jinping Gan
Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA
3 shared publications Nirmala Raghavan
Department of Pharmaceutical Candidate Optimization, ‡Chemistry, and §Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
3 shared publications- Haiying Zhang
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, NJ 08648, USA
2 shared publications - Hong Shen
Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, United States
2 shared publications Mingshe Zhu
Bristol-Myers Squibb Co
2 shared publicationsR. A. Morrison
Department of Metabolism and Pharmacokinetics, Preclinical Candidate Optimization, PO Box 5400, Princeton, NJ, 08543, USA; Department of Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ, 08543, USA
2 shared publications
Latest Publications
- Open Access
- 1 April 2019
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 47 (4) , 350-357
A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation
Suspended (SH), plated (PH) and sandwich-cultured hepatocytes (SCH) are commonly used models to predict in vivo transporter-mediated hepatic uptake (SH or PH) or biliary (SCH) clearance of drugs. When doing so, the total and plasma membrane abundance (PMA) of the transporter is assumed not to differ between hepatocytes and liver tissue (LT). This assumption has never been tested. Here, we tested this assumption by measuring the total and PMA of transporters in human hepatocyte models vs. LT (total only) from which they were isolated. Total abundance of OATP1B1/2B1/1B3, OCT1, and OAT2 was not significantly different between the hepatocytes and LT. The same was true for the PMA of these transporters across the hepatocyte models. In contrast, total abundance of the sinusoidal efflux transporter, MRP3, and the canalicular efflux transporters, MRP2 and P-gp, was significantly greater (P<0.05) in SCH vs. LT. Of the transporters tested, only the percent PMA of OATP1B1, P-gp and MRP3, in SCH (82.8±7.3%, 57.5±10.9%, 69.3±5.7%) was significantly greater (P<0.05) than in SH (73.3 ±6.4%, 27.4±6.4%, 53.6±4.1%). If the transporters measured in the plasma membrane are functional and the PMA in SH is representative of that in LT, these data suggest that SH, PH, and SCH will result in equal prediction of hepatic uptake clearance of drugs mediated by the transporters tested above. However, SCH will predict higher sinusoidal efflux and biliary clearance of drugs if the change in PMA of these transporters is not taken into consideration.
- 1 April 2019
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 47 (4) , 350-357
Open AccessA Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation
Suspended (SH), plated (PH) and sandwich-cultured hepatocytes (SCH) are commonly used models to predict in vivo transporter-mediated hepatic uptake (SH or PH) or biliary (SCH) clearance of drugs. When doing so, the total and plasma membrane abundance (PMA) of the transporter is assumed not to differ between hepatocytes and liver tissue (LT). This assumption has never been tested. Here, we tested this assumption by measuring the total and PMA of transporters in human hepatocyte models vs. LT (total only) from which they were isolated. Total abundance of OATP1B1/2B1/1B3, OCT1, and OAT2 was not significantly different between the hepatocytes and LT. The same was true for the PMA of these transporters across the hepatocyte models. In contrast, total abundance of the sinusoidal efflux transporter, MRP3, and the canalicular efflux transporters, MRP2 and P-gp, was significantly greater (P<0.05) in SCH vs. LT. Of the transporters tested, only the percent PMA of OATP1B1, P-gp and MRP3, in SCH (82.8±7.3%, 57.5±10.9%, 69.3±5.7%) was significantly greater (P<0.05) than in SH (73.3 ±6.4%, 27.4±6.4%, 53.6±4.1%). If the transporters measured in the plasma membrane are functional and the PMA in SH is representative of that in LT, these data suggest that SH, PH, and SCH will result in equal prediction of hepatic uptake clearance of drugs mediated by the transporters tested above. However, SCH will predict higher sinusoidal efflux and biliary clearance of drugs if the change in PMA of these transporters is not taken into consideration.
- Open Access
- 1 February 2017
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 360 (2) , 341-342
Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1
This letter to editor is to provide commentary on results presented in “Transport of lamivudine [(−)- β -l-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3” reported by [Minuesa et al
- 1 February 2017
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 360 (2) , 341-342
Open AccessTenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1
This letter to editor is to provide commentary on results presented in “Transport of lamivudine [(−)- β -l-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3” reported by [Minuesa et al
- 5 December 2016
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 29 (12) , 2040-2057
Drug–Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization
The formation of drug–protein adducts is considered an important feature in the pharmacological and toxicological profiles of many drugs. Mechanistic insights into the role of specific protein adduct formation in pharmacology and toxicology remain scarce, partly due to the availability of tools to identify and characterize the specific protein adducts, and partly due to the scarcity of relevant in vitro and in vivo predictive models. This review serves to provide a review on the current state of science on the chemistry, toxicology, and methods of detection and characterization of drug–protein adducts and to offer some perspective on the future directions of research into the role of protein adducts in drug effects and toxicity.
- 5 December 2016
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 29 (12) , 2040-2057
Drug–Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization
The formation of drug–protein adducts is considered an important feature in the pharmacological and toxicological profiles of many drugs. Mechanistic insights into the role of specific protein adduct formation in pharmacology and toxicology remain scarce, partly due to the availability of tools to identify and characterize the specific protein adducts, and partly due to the scarcity of relevant in vitro and in vivo predictive models. This review serves to provide a review on the current state of science on the chemistry, toxicology, and methods of detection and characterization of drug–protein adducts and to offer some perspective on the future directions of research into the role of protein adducts in drug effects and toxicity.
- Open Access
- 1 September 2016
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 6 (5) , 460-467
Tissue distribution and tumor uptake of folate receptor–targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration
- 1 September 2016
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 6 (5) , 460-467
Open AccessTissue distribution and tumor uptake of folate receptor–targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration
- Open Access
- 1 June 2016
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 44 (6) , 809-820
Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and Rearrangement
Daclatasvir is a first-in-class, potent and selective inhibitor of the hepatitis C virus nonstructural protein 5A replication complex. In support of nonclinical studies during discovery and exploratory development, liquid chromatography - tandem mass spectrometry and NMR were used in connection with synthetic and radiosynthetic approaches to investigate the biotransformation of daclatasvir in vitro and in the cynomolgus monkey, dog, mouse, and rat. The results of these studies indicated that disposition of daclatasvir was accomplished mainly by release of unchanged daclatasvir into bile and feces, and, secondarily, by oxidative metabolism. Cytochromes P450 were the main enzymes involved in the metabolism of daclatasvir. Oxidative pathways included δ-oxidation of the pyrrolidine moiety, resulting in ring opening to an aminoaldehyde intermediate followed by an intramolecular reaction between the aldehyde and the proximal imidazole nitrogen atom. Despite robust formation of the resulting metabolite in multiple systems, rates of covalent binding to protein associated with metabolism of daclatasvir were modest (55.2 - 67.8 pmol/mg/h) in NADPH-supplemented liver microsomes (human, monkey, rat) suggesting that intramolecular rearrangement was favored over intermolecular binding in the formation of this metabolite. This biotransformation profile supported the continued development of daclatasvir, which is now marketed for the treatment of chronic HCV infection.
- 1 June 2016
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 44 (6) , 809-820
Open AccessBiotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and Rearrangement
Daclatasvir is a first-in-class, potent and selective inhibitor of the hepatitis C virus nonstructural protein 5A replication complex. In support of nonclinical studies during discovery and exploratory development, liquid chromatography - tandem mass spectrometry and NMR were used in connection with synthetic and radiosynthetic approaches to investigate the biotransformation of daclatasvir in vitro and in the cynomolgus monkey, dog, mouse, and rat. The results of these studies indicated that disposition of daclatasvir was accomplished mainly by release of unchanged daclatasvir into bile and feces, and, secondarily, by oxidative metabolism. Cytochromes P450 were the main enzymes involved in the metabolism of daclatasvir. Oxidative pathways included δ-oxidation of the pyrrolidine moiety, resulting in ring opening to an aminoaldehyde intermediate followed by an intramolecular reaction between the aldehyde and the proximal imidazole nitrogen atom. Despite robust formation of the resulting metabolite in multiple systems, rates of covalent binding to protein associated with metabolism of daclatasvir were modest (55.2 - 67.8 pmol/mg/h) in NADPH-supplemented liver microsomes (human, monkey, rat) suggesting that intramolecular rearrangement was favored over intermolecular binding in the formation of this metabolite. This biotransformation profile supported the continued development of daclatasvir, which is now marketed for the treatment of chronic HCV infection.
- 20 November 2015
- Published by Royal Society of Chemistry (RSC)
- p. 247-262
Metabolomics-Based Approaches to Determine Drug Metabolite Profiles
Analytical technology forms the backbone of all absorption, distribution, metabolism and excretion (ADME)-related research and by far the most important single analytical technology is mass spectrometry (MS). The introduction of routine use high resolution high-resolution (HR) mass spectrometers over the last decade has provided an opportunity to greatly improve and enhance ADME scientists' abilities to conduct both qualitative and quantitative profiling of drug metabolites. Two of the most challenging tasks in metabolite identification by LC/MS are: (1) the rapid assignment of full scan and MS/MS spectra obtained from in vitro samples during the candidate optimization phase; and (2) the comprehensive detection and structural elucidation of all drug-related metabolites, including those that could be considered trace, either arising from predictable or unpredictable biotransformations in the presence of large amounts of complex interference ions from endogenous components. HR-MS can play a unique role in both of these key activities as well as other workflows in the ADME-related realm. This chapter will consider the utility of HR-MS in multiple aspects of drug metabolite detection in candidate optimization and characterization.
- 20 November 2015
- Published by Royal Society of Chemistry (RSC)
- p. 247-262
Metabolomics-Based Approaches to Determine Drug Metabolite Profiles
Analytical technology forms the backbone of all absorption, distribution, metabolism and excretion (ADME)-related research and by far the most important single analytical technology is mass spectrometry (MS). The introduction of routine use high resolution high-resolution (HR) mass spectrometers over the last decade has provided an opportunity to greatly improve and enhance ADME scientists' abilities to conduct both qualitative and quantitative profiling of drug metabolites. Two of the most challenging tasks in metabolite identification by LC/MS are: (1) the rapid assignment of full scan and MS/MS spectra obtained from in vitro samples during the candidate optimization phase; and (2) the comprehensive detection and structural elucidation of all drug-related metabolites, including those that could be considered trace, either arising from predictable or unpredictable biotransformations in the presence of large amounts of complex interference ions from endogenous components. HR-MS can play a unique role in both of these key activities as well as other workflows in the ADME-related realm. This chapter will consider the utility of HR-MS in multiple aspects of drug metabolite detection in candidate optimization and characterization.
- 11 June 2015
- Published by Taylor & Francis in Xenobiotica
- Vol. 46 (1) , 52-64
Characterization of ADME properties of [14C]asunaprevir (BMS-650032) in humans
1. Asunaprevir (ASV, BMS-650032), a highly selective and potent NS3 protease inhibitor, is currently under development for the treatment of chronic hepatic C virus infection. This study describes in vivo biotransformation in humans and the identification of metabolic enzymes of ASV. 2. Following a single oral dose of [14C]ASV to humans, the majority of radioactivity (>73% of the dose) was excreted in feces with In vitro studies with human cDNA expressed CYP enzymes and with human liver microsomes (HLM) in the presence of selective chemical inhibitors demonstrated that ASV was primarily catalyzed by CYP3A4 and CYP3A5.
- 11 June 2015
- Published by Taylor & Francis in Xenobiotica
- Vol. 46 (1) , 52-64
Characterization of ADME properties of [14C]asunaprevir (BMS-650032) in humans
1. Asunaprevir (ASV, BMS-650032), a highly selective and potent NS3 protease inhibitor, is currently under development for the treatment of chronic hepatic C virus infection. This study describes in vivo biotransformation in humans and the identification of metabolic enzymes of ASV. 2. Following a single oral dose of [14C]ASV to humans, the majority of radioactivity (>73% of the dose) was excreted in feces with In vitro studies with human cDNA expressed CYP enzymes and with human liver microsomes (HLM) in the presence of selective chemical inhibitors demonstrated that ASV was primarily catalyzed by CYP3A4 and CYP3A5.
- 2 March 2012
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 25 (3) , 556-571
Cytochrome P450 11A1 Bioactivation of a Kinase Inhibitor in Rats: Use of Radioprofiling, Modulation of Metabolism, and Adrenocortical Cell Lines to Evaluate Adrenal Toxicity
A drug candidate, BMS-A ((N-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-3-fluorophenyl)-1-(4-fluorophenyl) 2-oxo-1,2-dihydropyridine- 3-carboxamide)), was associated with dose- and time-dependent vacuolar degeneration and necrosis of the adrenal cortex following oral administration to rats. Pretreatment with 1-aminobenzotriazole (ABT), a nonspecific P450 inhibitor, ameliorated the toxicity. In vivo and in vitro systems, including adrenal cortex-derived cell lines, were used to study the mechanism responsible for the observed toxicity. Following an oral dose of the C-14 labeled compound, two hydroxylated metabolites of the parent (M2 and M3) were identified as prominent species found only in adrenal glands and testes, two steroidogenic organs. In addition, a high level of radioactivity was covalently bound to adrenal tissue proteins, 40% of which was localized in the mitochondrial fraction. ABT pretreatment reduced localization of radioactivity in the adrenal gland. Low levels of radioactivity bound to proteins were also observed in testes. Both M3 and covalent binding to proteins were found in incubations with mitochondrial fraction isolated from adrenal tissue in the presence of NADPH. In vitro formation of M3 and covalent binding to proteins were not affected by addition of GSH or a CYP11B1/2 inhibitor, metyrapone (MTY), but were inhibited by ketoconazole (KTZ) and a CYP11A1 inhibitor, R-(+)-aminoglutethimide (R-AGT). BMS-A induced apoptosis in a mouse adrenocortical cell line (Y-1) but not in a human cell line (H295R). Metabolite M3 and covalent binding to proteins were also produced in Y-1 and to a lesser extent in H295R cells. The cell toxicity, formation of M3, and covalent binding to proteins were all diminished by R-AGT but not by MTY. These results are consistent with a CYP11A1-mediated bioactivation to generate a reactive species, covalent binding to proteins, and subsequently rat adrenal toxicity. The thorough understanding of the metabolism-dependent adrenal toxicity was useful to evaluate cross-species adrenal toxicity potential of this compound and related analogues.
- 2 March 2012
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 25 (3) , 556-571
Cytochrome P450 11A1 Bioactivation of a Kinase Inhibitor in Rats: Use of Radioprofiling, Modulation of Metabolism, and Adrenocortical Cell Lines to Evaluate Adrenal Toxicity
A drug candidate, BMS-A ((N-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-3-fluorophenyl)-1-(4-fluorophenyl) 2-oxo-1,2-dihydropyridine- 3-carboxamide)), was associated with dose- and time-dependent vacuolar degeneration and necrosis of the adrenal cortex following oral administration to rats. Pretreatment with 1-aminobenzotriazole (ABT), a nonspecific P450 inhibitor, ameliorated the toxicity. In vivo and in vitro systems, including adrenal cortex-derived cell lines, were used to study the mechanism responsible for the observed toxicity. Following an oral dose of the C-14 labeled compound, two hydroxylated metabolites of the parent (M2 and M3) were identified as prominent species found only in adrenal glands and testes, two steroidogenic organs. In addition, a high level of radioactivity was covalently bound to adrenal tissue proteins, 40% of which was localized in the mitochondrial fraction. ABT pretreatment reduced localization of radioactivity in the adrenal gland. Low levels of radioactivity bound to proteins were also observed in testes. Both M3 and covalent binding to proteins were found in incubations with mitochondrial fraction isolated from adrenal tissue in the presence of NADPH. In vitro formation of M3 and covalent binding to proteins were not affected by addition of GSH or a CYP11B1/2 inhibitor, metyrapone (MTY), but were inhibited by ketoconazole (KTZ) and a CYP11A1 inhibitor, R-(+)-aminoglutethimide (R-AGT). BMS-A induced apoptosis in a mouse adrenocortical cell line (Y-1) but not in a human cell line (H295R). Metabolite M3 and covalent binding to proteins were also produced in Y-1 and to a lesser extent in H295R cells. The cell toxicity, formation of M3, and covalent binding to proteins were all diminished by R-AGT but not by MTY. These results are consistent with a CYP11A1-mediated bioactivation to generate a reactive species, covalent binding to proteins, and subsequently rat adrenal toxicity. The thorough understanding of the metabolism-dependent adrenal toxicity was useful to evaluate cross-species adrenal toxicity potential of this compound and related analogues.
- Open Access
- 1 July 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (29) , 25419-25425
Drug Metabolite Profiling and Identification by High-resolution Mass Spectrometry
- 1 July 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (29) , 25419-25425
Open AccessDrug Metabolite Profiling and Identification by High-resolution Mass Spectrometry
- 30 June 2011
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 192 (1-2) , 56-59
Overview of strategies for addressing BRIs in drug discovery: Impact on optimization and design
- 30 June 2011
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 192 (1-2) , 56-59
Overview of strategies for addressing BRIs in drug discovery: Impact on optimization and design